EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?

Silvia Corcione, Ilaria De Benedetto iD, Nour Shbaklo, Giulia Torsello, Tommaso Lupia iD, Gabriele Bianco iD, Rossana Cavallo, Luca Brazzi iD, Giorgia Montrucchio iD, Francesco Giuseppe De Rosa iD

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms24054767 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Silvia Corcione und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Ceftazidime, Drug Combinations, Klebsiella Infections. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The continuous spread of carbapenem-resistant Klebsiella pneumoniae (CP-Kp) strains presents a severe challenge to the healthcare system due to limited therapeutic options and high mortality. Since its availability, ceftazidime/avibactam (C/A) has become a first-line option against KPC-Kp, but C/A-resistant strains have been reported increasingly, especially with pneumonia or prior suboptimal blood exposure to C/A treatment. A retrospective, observational study was conducted with all patients admitted to the Intensive Care Unit (ICU) dedicated to COVID-19 patients at the City of Health & Sciences in Turin, between 1 May 2021 and 31 January 2022, with the primary endpoint to study strains with resistance to C/A, and secondly to describe the characteristics of this population, with or without previous exposure to C/A. Seventeen patients with colonization or invasive infection due to Klebsiella pneumoniae, C/A resistance, and susceptibility to meropenem (MIC = 2 µg/L) were included; the blaKPC genotype was detected in all isolates revealing D179Y mutation in the blaKPC-2 (blaKPC-33) gene. Cluster analysis showed that 16 out of the 17 C/A-resistant KPC-Kp isolates belonged to a single clone. Thirteen strains (76.5%) were isolated in a 60-day period. Only some patients had a previous infection with non-mutant KPC at other sites (5; 29.4%). Eight patients (47.1%) underwent previous large-spectrum antibiotic treatment, and four patients (23.5%) had prior treatment with C/A. The secondary spread of the D179Y mutation in the blaKPC-2 during the COVID-19 pandemic needs to be addressed constantly by an interdisciplinary interaction between microbiologists, infection control personnel, clinicians, and infectious diseases consultants to properly diagnose and treat patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCeftazidimeDrug CombinationsKlebsiella InfectionsKlebsiella pneumoniaeMeropenemDrug Resistance, BacterialHumansBacterial Proteinsbeta-LactamasesCOVID-19Intensive Care UnitsMicrobial Sensitivity TestsPandemicsRetrospective StudiesAzabicyclo Compounds

Stichwörter der Autor:innen

D179YKPCcarbapenemasesceftazidime/avibactamresistance

Substanzen

Anti-Bacterial AgentsBacterial Proteinsbeta-LactamasesCeftazidimeDrug CombinationsMeropenemavibactam, ceftazidime drug combinationAzabicyclo Compounds

Autor:innen und Institutionen

  • Department of Medical Sciences, Infectious Diseases, University of Turin, 10124 Turin, Italy.
  • School of Medicine, Tufts University School of Medicine, Boston, MA 02111, USA.
  • Department of Anesthesia, Intensive Care and Emergency-'Città della Salute e della Scienza' Hospital, 10126 Turin, Italy.
  • Infectious Diseases Unit, Cardinal Massaia Hospital, 14100 Asti, Italy.
  • Microbiology and Virology Unit, University Hospital Città della Salute e della Scienza di Torino, 10126 Turin, Italy.

ORCID-Profile: Ilaria De Benedetto, Tommaso Lupia, Gabriele Bianco, Luca Brazzi, Giorgia Montrucchio, Francesco Giuseppe De Rosa

Zitieren

APA

Corcione, S., De Benedetto, I., Shbaklo, N., Torsello, G., Lupia, T., Bianco, G., Cavallo, R., Brazzi, L., Montrucchio, G., & De Rosa, F. G. (2023). Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms24054767

Vancouver

Corcione S, De Benedetto I, Shbaklo N, Torsello G, Lupia T, Bianco G, et al. Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms24054767

BibTeX
@article{Corcione2023,
  author = {Corcione, Silvia and De Benedetto, Ilaria and Shbaklo, Nour and Torsello, Giulia and Lupia, Tommaso and Bianco, Gabriele and Cavallo, Rossana and Brazzi, Luca and Montrucchio, Giorgia and De Rosa, Francesco Giuseppe},
  title = {Ceftazidime-Avibactam (C/A) Resistant, Meropenem Sensitive KPC-Producing Klebsiella pneumoniae in ICU Setting: We Are What We Are Treated with?},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms24054767}
}
Kostenlos starten →